Alvotech opens state-of-the-art biosimilar facility in Iceland
The new facility will significantly increase Alvotech’s production capacity enabling the group to produce higher yields at lower costs.
Alvotech, an independent sister company of Alvogen, has opened a new state-of-the-art facility, dedicated to the development and manufacturing of biosimilar monoclonal antibodies (mAbs). The opening of this biologics manufacturing plant marks a significant milestone for both Alvogen and Alvotech.
Through the Alvotech-Alvogen alliance, Alvogen directly benefits from the growth of Alvotech due the increased supply of products coming to market. Alvotech currently runs five offices in Iceland, Germany, Switzerland and Malta, which in turn helps Alvogen to maximise its distribution of the products. Alvogen is already advanced in the distribution of biosimilars through its relationship with Hospira/Pfizer and it currently distributes products in 35 countries with a target revenue generation of $3 billion by 2020.
Alvotech has worked with the FDA and European EMA regulatory agencies to design and build a facility complying with the highest quality standards. The 13,000 m2 facility is located the science park of the University of Iceland in Reykjavik. Iceland offers a favourable operating environment with a strong regulatory system and a convenient geographical location. Furthermore the new facility will significantly increase Alvotech’s production capacity enabling the group to produce higher yields at lower costs.
Robert Wessman, Chairman and CEO of Alvogen said: “The relationship we have with Alvotech continues to form a central component of our own growth strategy as we continue to expand our global network. The opening of this new facility, helps us to establish ourselves as leaders in the biopharmaceutical industry. Our focus is on our patients and, with this new state-of-the-art manufacturing facility, combined with our commercial network, we are able to continue to deliver high quality products to our customers.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance